Monitoring of minimal residual disease i
β
Wolfgang Kern; Claudia Haferlach; Torsten Haferlach; Susanne Schnittger
π
Article
π
2007
π
John Wiley and Sons
π
English
β 587 KB
## Abstract Two highly sensitive methods, multiparameter flow cytometry (MFC) and realβtime quantitative PCR (RQβPCR), are increasingly used to monitor minimal residual disease (MRD) and to guide riskβadapted management in acute myeloid leukemia (AML). An independent prognostic impact has been demo